Objective To observe the efficacy of camrelizumab combined with low-dose albumin paclitaxel and platinum first-line therapy on elderly patients with advanced lung squamous cell carcinoma (LSCC). Methods 98 elderly patients with advanced LSCC in the hospital from January 2020 to January 2023 were included in the study and grouped according to treatment method. 49 cases in the control group were treated with low-dose albumin paclitaxel combined with carboplatin first-line chemotherapy, and 49 cases in the treatment group were given camrelizumab combined with low-dose albumin paclitaxel and carboplatin first-line chemotherapy. The short-term efficacy, and levels of cytokeratin 19 fragment (CY-FRA21-1) and squamous cell carcinoma antigen (SCC) before and after treatment and safety and prognosis survival status were evaluated in the two groups. Results Compared with the control group, the objective remission rate in the treatment group was significantly enhanced (P<0.05). The levels of CY-FRA21-1 and SCC in the treatment group were significantly decreased after 4 cycles of treatment compared with those in the control group (P<0.05). There were no significant differences in adverse reactions between groups (P>0.05). The cumulative survival rate in the treatment group was higher than that in the control group (P<0.05). Conclusion On the basis of low-dose albumin paclitaxel and platinum therapy, combination of camrelizumab can effectively enhance the objective remission rate of elderly patients with advanced lung squamous cell carcinoma, improve the levels of tumor markers and enhance the survival rate of patients, and the safety is acceptable